Joseph Graney, MD
Pediatrics · Auburn, NYNPI 1225021892
Payments from drug & device makers
Across 156 payments — averaging $16.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$383
- Novo Nordisk$365
- AbbVie$283
- Lilly USA, LLC$220
- Boehringer Ingelheim$188
- Pfizer$180
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,638100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 23 | $383 |
| Novo Nordisk | 22 | $365 |
| AbbVie | 15 | $283 |
| Lilly USA, LLC | 14 | $220 |
| Boehringer Ingelheim | 11 | $188 |
| Pfizer | 12 | $180 |
| Merck | 11 | $154 |
| Johnson & Johnson | 6 | $148 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $98 |
| Corium, LLC | 5 | $81 |
| Kowa Pharmaceuticals America, Inc. | 3 | $60 |
| IBSA Pharma Inc. | 3 | $50 |
| Sanofi Pasteur Inc. | 3 | $49 |
| Seqirus USA Inc | 1 | $41 |
| Collegium Pharmaceutical, Inc. | 2 | $36 |
| Amarin Pharma, Inc. | 2 | $32 |
| Amgen | 2 | $29 |
| Almatica Pharma LLC | 1 | $24 |
| Abbott | 1 | $23 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $21 |
| Exact Sciences | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Shield Therapeutics Inc | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Alkermes, Inc. | 1 | $15 |
| AstraZeneca | 1 | $14 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
How this compares
$2,638 in reported general payments places this provider in the 95th percentile of 4,055 pediatrics providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 58 | $68,218 |
| EliquisApixaban | 54 | $49,445 |
| XareltoRivaroxaban | 43 | $46,585 |
| RybelsusSemaglutide | 22 | $28,502 |
| JardianceEmpagliflozin | 22 | $25,827 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $25,636 |
| TrulicityDulaglutide | 14 | $12,975 |
| MyrbetriqMirabegron | 21 | $12,032 |
| Levothyroxine Sodium | 215 | $6,130 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,224 |
| Atorvastatin Calcium | 365 | $3,488 |
| Metoprolol Succinate | 140 | $2,523 |
| Rosuvastatin Calcium | 181 | $2,278 |
| Mometasone Furoate | 35 | $2,266 |
| Bupropion XlBupropion Hcl | 51 | $1,968 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $365 | $96,72080 claims |
| PfizerEliquis | $180 | $49,44554 claims |
| Johnson & JohnsonXarelto | $148 | $46,58543 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $383 | $29,86049 claims |
| Boehringer IngelheimJardiance | $188 | $25,82722 claims |
| Lilly USA, LLCTrulicity | $220 | $12,97514 claims |
| AbbVieSynthroid | $283 | $90518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,055 pediatrics providers in New York.
Other pediatrics in Auburn
- Giancarlo GuidoBronx$3.9M
- Janet CaseyRochester$3.4M
- Michael PichicheroRochester$1.5M
- Rudolph LeibelNew York$1M
- Philip OzuahBronx$1M
- Kevin CurranNew York$842K
- Joan Decelie-GermanaGreat Neck$840K
- Shakeel ModakNew York$774K
- Elaine AbramsNew York$637K
- Dawn WaheziBronx$444K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.